Subscribe to RSS - diabetes supplies

diabetes supplies

Mandatory mail order? Seniors concerned


ALEXANDRIA, Va. – A survey that suggests seniors are leery of mandatory mail-order pharmacy services may cast a long shadow on Medicare’s national mail-order program for diabetes supplies.

Glooko receives FDA clearance, hires CEO


PALO ALTO, Calif. – In a busy week, Glooko saw one of its diabetes monitoring apps get FDA clearance, and announced the hiring of a new CEO, according to news reports.

Moderate growth expected for diabetes market, study says


TORONTO – The U.S. market for diabetes care devices is expected to grow to nearly $16 billion by 2017, according to a new study from Millennium Research Group, a research organization specializing in medical technology market intelligence.

Box: Diabetes supply



Diabetes market in transition

Stakeholders see an uptick in interest toward related markets, such as ostomy, urology, wound care

Nowhere is the impact of Medicare competitive bidding more evident than in diabetes supply. 

OIG work plan includes several new reviews for DME


WASHINGTON – What durable medical equipment will bear the brunt of the Office of Inspector General’s (OIG’s) scrutiny next year? Diabetes supplies.

DME MACs issue re-supply guidance


BALTIMORE – As promised, the four CMS medical directors have released an FAQ on re-supplies. CMS announced in a June bulletin that items that need periodic replacement, like CPAP supplies, must be non-functioning.

IR: 'Will they do it for other products?'


YARMOUTH, Maine – CMS's plan to use inherent reasonableness (IR) to set prices for retail diabetes supplies could be a sign of things to come, say industry stakeholders.

IR makes a comeback?

CMS proposes using inherent reasonableness to set payment amounts for non-mail-order diabetes supplies

WASHINGTON – CMS announced late on Friday that it plans to host a public meeting next month to consult with stakeholders on adjusting Medicare payment amounts for non-mail order diabetes supplies.

More bad news for AmMed


NASHVILLE, Tenn. – AmMed Direct will pay $18 million to settle claims that it used a “bait-and-switch” scheme for diabetes testing supplies.